Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met. Data as of 17/09/2026.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: -3.96%
Price change 2019 → 2020: 21.02%
Price change 2020 → 2021: 26.36%
Price change 2021 → 2022: 19.36%
Price change 2022 → 2023: -4.11%
Price change 2023 → 2024: 14.67%
Price change 2024 → 2025: 28.58%
Price change 2025 → 2026: 13.79%
Price change 2026 (year to date): 13.38%
Financial growth
Revenue CAGR (8 years): 9.33%
Earnings CAGR (8 years): -4.15%
Growth status: positive trend (>1%/yr) in revenue OR earnings, but not both.
Debt
Debt-to-equity ratio: 69068000000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 25.79
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 2.25% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ABBV" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| AbbVie Inc. | 28.0 | – | +9.5 % | 🔒 |
| AstraZeneca PLC | 18.5 | 0.61 | +3.9 % | – |
| Pfizer Inc. | 9.8 | 0.78 | −0.5 % | – |
| Sanofi | 8.8 | 0.28 | +2.5 % | – |
| EssilorLuxottica S.A. | 33.6 | 0.37 | +14.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|